• 13732 Citations
  • 56 h-Index
1982 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Dae Seog Heo is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 37 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Survival Medicine & Life Sciences
Epidermal Growth Factor Receptor Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Korea Medicine & Life Sciences
Cisplatin Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1982 2019

A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer

Kim, Y. J., Keam, B., Ock, C. Y., Song, S., Kim, M., Kim, S. H., Kim, K. H., Kim, J. S., Kim, T. M., Kim, D. W., Lee, J. S. & Heo, D. S., 1 Oct 2019, In : Lung Cancer. 136, p. 122-128 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Small Cell Lung Carcinoma
Paclitaxel
Disease-Free Survival
Etoposide
Platinum

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer

Ock, C. Y., Yoo, S. H., Keam, B., Kim, M., Kim, T. M., Jeon, Y. K., Kim, D. W., Chung, D. H. & Heo, D. S., 1 Sep 2019, In : The Korean journal of internal medicine. 34, 5, p. 1116-1124 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
Non-Small Cell Lung Carcinoma
Disease-Free Survival
Survival
Multivariate Analysis
crizotinib
Non-Small Cell Lung Carcinoma
Drug Therapy
Disease-Free Survival
Cell Death
Confidence Intervals

Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations

Lee, Y., Kim, T. M., Kim, D. W., Kim, S., Kim, M., Keam, B., Ku, J-L. & Heo, D. S., 1 Sep 2019, In : Journal of Thoracic Oncology. 14, 9, p. 1556-1566 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Insertional Mutagenesis
Exons
Protein-Tyrosine Kinases
Inhibitory Concentration 50
Ethylnitrosourea
3 Citations (Scopus)

Acquired resistance of MET-amplified non-small cell lung cancer cells to the MET inhibitor capmatinib

Kim, S., Kim, T. M., Kim, D. W., Kim, S., Kim, M., Ahn, Y. O., Keam, B. & Heo, D. S., 1 Jul 2019, In : Cancer Research and Treatment. 51, 3, p. 951-962 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
1-Phosphatidylinositol 4-Kinase
Cell Line
Protein-Tyrosine Kinases